Command Palette

Search for a command to run...

PPLPHARMA

158.750.15 (0.09%)

Quarterly ResultsProfit & LossBalance SheetCash Flow

Key Insights

POSITIVE
  • Net Sales increased significantly in the latest quarter (202503) to ₹2754.07 crore from ₹2204.22 crore, showing strong growth.
  • Operating margin improved dramatically to 7.79% in Q3 2025, a recovery from previous lows, indicating better cost management.
  • Net profit rebounded to ₹153.5 crore in Q3 2025, compared to a minimal profit of ₹3.68 crore in Q2 2024.
NEGATIVE
  • Company experienced a cash flow shortfall with a 10% decrease this year [Dummy Data]
  • Company’s strategic partnerships have yet to generate expected growth. [Dummy Data]
  • Company’s EBITDA shrank at a CAGR of -8% over the past 3 years. [Dummy Data]
Quarterly Results Data
FieldTrendMar 24Jun 24Sep 24Dec 24Mar 25Jun 25Sep 25Dec 25
Revenue
2,552.361,951.142,241.752,204.222,754.071,933.712,043.722,139.87
Expenses
2,332.782,038.162,2002,166.602,539.522,110.442,170.292,246.12
Operating Profit
219.58-87.0241.7537.62214.55-176.73-126.57-106.25
Other Income
26.3819.5461.1112.1342.0358.4065.6043.24
Interest
114.22106.96107.64103.31103.6886.1582.4289.24
Depreciation
196.13184.55192.22196.81242.76197.28202.84212.74
Profit Before Tax
227.48-45.08120.1266.80272.80-79.02-46.18-93.86
Tax
126.2143.5697.5363.12119.302.6853.0442.33
Net Profit
101.27-88.6422.593.68153.50-81.70-99.22-136.19
EPS in Rs
0.77-0.670.170.031.16-0.62-0.75-1.03